Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
{{output}}
Neratinib is a tyrosine kinase inhibitor that is used for the therapy of patients with HER2+ breast tumors. However, despite its clinical benefit, resistance to the drug may arise. Here we have created cellular models of neratinib resistance to investigate the... ...